Latest Mapatumumab Stories
-Preliminary Data Show Seven of 17 Evaluable Patients Achieved an Objective Tumor Response by End of Four Treatment Cycles- TUSTIN, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
- Albuferon(R) for hepatitis C, LymphoStat-B(R) for lupus and ABthrax(R) for inhalation anthrax all progressing rapidly toward commercialization - - GSK Phase 3 trial of darapladib underway in chronic coronary heart disease - - HGS provides 2009 financial guidance; expects less than $25 million net cash burn - ROCKVILLE, Md., Jan.
MONTREAL, Jan. 8 /PRNewswire/ - Aegera Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.
ImClone Systems, a developer of novel antibodies to treat cancer, has initiated patient enrollment for its disease-directed Phase II clinical trial of IMC-1121B in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Cytokinetics, Incorporated (NASDAQ: CYTK), reported revenues from research and development collaborations of $3.1 million for the third quarter of 2008.
Infinity Pharmaceuticals, a cancer drug discovery and development company, has announced that it has met pre-specified criteria to expand both arms of its ongoing Phase II clinical trial evaluating IPI-504, its lead heat shock protein 90 inhibitor, in patients with advanced non-small cell lung cancer.
OXiGENE, a biopharmaceutical company, has reported positive interim results from an ongoing Phase II study of Zybrestat in patients with platinum-resistant ovarian cancer.
Onconova Therapeutics, Inc. announced today the publication of positive results from a first-in-human Phase I clinical trial of its lead anticancer drug, ON 01910.Na, in advanced refractory solid tumors.
Proteolix has reported positive data from a Phase I clinical trial of carfilzomib in patients with advanced solid tumors.
- The act of sweetening by admixture of some saccharine substance.